Serum cytokine profiles and metabolic tumor burden in patients with non-small cell lung cancer undergoing palliative thoracic radiation therapy

Hanne A. Eide, MD; Ingerid Skjei Knudtsen, MSc; Vandana Sandhu, PhD; Ayca M. Løndalen, MD; Ann Rita Halvorsen, MSc; Azadeh Abravan, MSc; Elin H. Kure, PhD; Trond V. Bogsrud, MD, PhD; Odd Terje Brustugun, MD, PhD; Jon Amund Kyte, MD, PhD; Eirik Malinen, PhD; Åslaug Helland, MD, PhD

Advances in Radiation Oncology (Apr 2018)

Serum cytokine profiles and metabolic tumor burden in patients with non-small cell lung cancer undergoing palliative thoracic radiation therapy

Hanne A. Eide, MD,
Ingerid Skjei Knudtsen, MSc,
Vandana Sandhu, PhD,
Ayca M. Løndalen, MD,
Ann Rita Halvorsen, MSc,
Azadeh Abravan, MSc,
Elin H. Kure, PhD,
Trond V. Bogsrud, MD, PhD,
Odd Terje Brustugun, MD, PhD,
Jon Amund Kyte, MD, PhD,
Eirik Malinen, PhD,
Åslaug Helland, MD, PhD

Affiliations

Hanne A. Eide, MD: Department of Cancer Genetics, Institute for Cancer Research, Oslo University Hospital–The Norwegian Radium Hospital, Oslo, Norway; Department of Oncology, Oslo University Hospital–The Norwegian Radium Hospital, Oslo, Norway
Ingerid Skjei Knudtsen, MSc: Department of Physics, University of Oslo, Oslo, Norway; Department of Medical Physics, Oslo University Hospital, Oslo, Norway
Vandana Sandhu, PhD: Department of Cancer Genetics, Institute for Cancer Research, Oslo University Hospital–The Norwegian Radium Hospital, Oslo, Norway
Ayca M. Løndalen, MD: Department of Radiology and Nuclear Medicine, Oslo University Hospital, Norway
Ann Rita Halvorsen, MSc: Department of Cancer Genetics, Institute for Cancer Research, Oslo University Hospital–The Norwegian Radium Hospital, Oslo, Norway
Azadeh Abravan, MSc: Department of Physics, University of Oslo, Oslo, Norway; Department of Medical Physics, Oslo University Hospital, Oslo, Norway
Elin H. Kure, PhD: Department of Cancer Genetics, Institute for Cancer Research, Oslo University Hospital–The Norwegian Radium Hospital, Oslo, Norway; Department of Natural Sciences and Environmental Health, University College of Southeast Norway, Bø in Telemark, Norway
Trond V. Bogsrud, MD, PhD: Department of Radiology and Nuclear Medicine, Oslo University Hospital, Norway; Department of Nuclear Medicine and PET-Centre, Aarhus University Hospital, Aarhus, Denmark
Odd Terje Brustugun, MD, PhD: Department of Cancer Genetics, Institute for Cancer Research, Oslo University Hospital–The Norwegian Radium Hospital, Oslo, Norway; Section of Oncology, Drammen Hospital, Vestre Viken Hospital Trust, Drammen, Norway
Jon Amund Kyte, MD, PhD: Department of Cancer Genetics, Institute for Cancer Research, Oslo University Hospital–The Norwegian Radium Hospital, Oslo, Norway; Department for Cell Therapy, Oslo University Hospital–The Norwegian Radium Hospital, Oslo, Norway
Eirik Malinen, PhD: Department of Physics, University of Oslo, Oslo, Norway; Department of Medical Physics, Oslo University Hospital, Oslo, Norway
Åslaug Helland, MD, PhD: Department of Cancer Genetics, Institute for Cancer Research, Oslo University Hospital–The Norwegian Radium Hospital, Oslo, Norway; Department of Oncology, Oslo University Hospital–The Norwegian Radium Hospital, Oslo, Norway; Institute of Clinical Medicine, University of Oslo, Norway; Corresponding author. Oslo University Hospital–The Norwegian Radium Hospital, Postboks 4953 Nydalen, 0424 Oslo, Norway.

Journal volume & issue: Vol. 3, no. 2
pp. 130 – 138

Abstract

Read online

Purpose: Radiation therapy effectively kills cancer cells and elicits local effects in the irradiated tissue. The aim of this study was to investigate the kinetics of cytokines in the serum of patients with lung cancer undergoing radiation therapy and to identify associations with metabolic tumor burden as determined by 2-deoxy-2-fluoro-D-glucose (18F-FDG) positron emission tomography (PET). Methods and materials: Forty-five patients with advanced non-small cell lung cancer were included in a phase 2 clinical trial and randomized between fractionated thoracic radiation therapy alone or concurrent with an epidermal growth factor receptor inhibitor. Blood was sampled at 4 different time points: prior to treatment, midtherapy, at the end of therapy, and 6 to 8 weeks after the start of treatment. The serum concentrations of 48 cytokines and 9 matrix metalloproteinases were measured with multiplex immunoassays. A subset of patients was examined by 18F-FDG PET/computed tomography before, during, and after radiation therapy. The maximum standardized uptake values (SUVmax) of the primary lung tumor, whole-body metabolic tumor volume, and total lesion glycolysis were calculated, and correlations between the PET parameters and cytokines were investigated. Results: The SUVmax decreased from baseline through midtherapy to posttherapy 18F-FDG PET/computed tomography (P = .018). The serum levels of C-C motif chemokine ligand (CCL) 23, CCL24, C-X3-C motif chemokine ligand 1, and interleukin-8 (C-X-C motif ligand [CXCL]8) were significantly correlated to SUVmax, metabolic tumor volume, and total lesion glycolysis before, during, and after radiation therapy. CXCL2 (P = .030) and CXCL6 (P = .010) decreased after the start of therapy and changed significantly across the sample time points. Serum concentrations of CCL15 (P = .031), CXCL2 (P = .028), and interleukin-6 (P = .007) were positively correlated to the irradiated volume during the second week of treatment. Conclusions: Cytokine serum levels vary and correlate with metabolic tumor burden in patients with advanced non-small cell lung cancer undergoing palliative thoracic radiation therapy.

Published in Advances in Radiation Oncology

ISSN: 2452-1094 (Online)
Publisher: Elsevier
Country of publisher: United States
LCC subjects: Medicine: Medicine (General): Medical physics. Medical radiology. Nuclear medicine; Medicine: Internal medicine: Neoplasms. Tumors. Oncology. Including cancer and carcinogens
Website: http://www.journals.elsevier.com/advances-in-radiation-oncology/

About the journal